Bank of America just raised its EUR/USD forecast
Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA), a biotech company with a market capitalization of $2.03 billion and a "GREAT" financial health score according to InvestingPro, saw its Chief Operating Officer Eben Tessari sell 17,300 shares of Class A Ordinary Share on June 16, 2025, for approximately $489,244. The shares were sold at prices ranging from $27.795 to $28.645, near the stock’s 52-week high of $30.69.
On the same day, Tessari also exercised options to acquire 6,500 shares of Kiniksa Pharmaceuticals at a price of $8.83, totaling $57,395. Following these transactions, Tessari directly owns 61,563 shares of the company. The stock has shown strong momentum, gaining over 53% in the past year, though it recently experienced a 7.5% decline over the past week.
The option exercise relates to Share Options that are exercisable until September 16, 2029. After the transaction, Tessari directly owns 38,500 Share Options.
These transactions were executed under a pre-arranged 10b5-1 trading plan adopted by Tessari on April 29, 2024.
In other recent news, Kiniksa Pharmaceuticals International has announced plans for a Phase 2/3 clinical trial of its drug KPL-387, which is designed for the treatment of recurrent pericarditis. The trial is expected to begin in mid-2025, with Phase 2 data anticipated in the second half of 2026. The study aims to determine the optimal dose and evaluate the time to treatment response at Week 24. Additionally, Kiniksa has introduced a new incentive plan, known as the KPL-387 Long-Term Incentive Plan (Executive 387 LTIP), to drive progress in the drug’s development. This plan includes cash awards, performance share units, and stock options for executive officers, contingent upon achieving key regulatory milestones. The incentives are structured to encourage timely submission of a biologics license application to the FDA and approval for commercial sale in the United States. Kiniksa’s strategic move reflects its commitment to advancing KPL-387 and highlights the company’s confidence in the drug’s potential.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.